Inhibitors of KRAS G12C have shown that directly targeting RAS is possible, but G12C is only one of many RAS driver mutations. Covalent targeting of another major variant, G12D, raises hope for treating other groups of patients with KRAS-mutant tumors.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Buscail, L., Bournet, B. & Cordelier, P. Nat. Rev. Gastroenterol. Hepatol. 17, 153–168 (2020).
Zheng, Q., Zhang, Z., Guiley, K. G. & Shokat, K. M. Nat. Chem. Biol. https://doi.org/10.1038/s41589-024-01565-w (2023).
Ganguly, A. K. et al. Biochemistry 37, 15631–15637 (1998).
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A. & Shokat, K. M. Nature 503, 548–551 (2013).
Zhang, Z., Guiley, K. Z. & Shokat, K. M. Nat. Chem. Biol. 18, 1177–1183 (2022).
Wang, X. et al. J. Med. Chem. 65, 3123–3133 (2022).
Hallin, J. et al. Nat. Med. 28, 2171–2182 (2022).
US National Library of Medicine. ClinicalTrials.gov https://classic.clinicaltrials.gov/show/NCT05737706 (2023).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
K.W. serves on advisory boards for Vibliome Therapeutics, Reactive Biosciences and Velurum Therapeutics and has equity in Vibliome and Velurum. K.W. has received funding from Revolution Medicines and Astellas Pharmaceuticals. K.W. has served as a consultant for Sanofi, AstraZeneca and Amgen.
Rights and permissions
About this article
Cite this article
Westover, K. Another KRAS variant trapped. Nat Chem Biol (2024). https://doi.org/10.1038/s41589-024-01556-x
Published:
DOI: https://doi.org/10.1038/s41589-024-01556-x
